Quick search:
Content Search
Result Content Research
Result Content Research
1 Fulcrum Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference
2 Fulcrum Therapeutics Announces US Food and Drug Administration Grants Fast Track Designation to Losmapimod for the
3 Fulcrum Therapeutics Appoints Judith A. Dunn, Ph.D. as President of Research and Development
4 Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results
5 Fulcrum Therapeutics Announces Pricing of Public Offering
6 Fulcrum Therapeutics Presents Published Structure of
7 Fulcrum Therapeutics Announces CEO Transition
8 Fulcrum Therapeutics Announces Closing of Public Offering
9 Fulcrum Therapeutics Presents Updated Data on Sickle Cell
10 Fulcrum Therapeutics Announces Promotion of Christopher Moxham, Ph.D., to Chief Scientific Officer
11 Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease
12 News Flash: Analysts Just Made A Huge Upgrade To Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Forecasts
13 Fulcrum Therapeutics to Host Virtual Key Opinion Leader Event Featuring FTX-6058 for Sickle Cell Disease
14 Fulcrum Therapeutics, Inc. (FULC) Reports Q1 Loss, Tops Revenue Estimates
15 Fulcrum Therapeutics Reports Recent Business Highlights and
16 Fulcrum Therapeutics, Evofem Biosciences Drug Candidates Receive FDA Fast Track Designation
17 Global Duchenne Muscular Dystrophy Drugs Market Insights Report 2021, Trends & Opportunities to 2026|Akashi Therapeutics Inc, Antisense Therapeutics Ltd, Beech Tree Labs Inc, Biogen Inc, Bioleaders Corp, etc – KSU | The Sentinel Newspaper
18 MyoKardia and Fulcrum Therapeutics Announce Multi-Target
19 Fulcrum Therapeutics Recognizes Rare Disease Day 2021
20 Fulcrum Therapeutics Announces Preclinical Proof-of-Concept Data for FTX-6058 at the Virtual 14th Annual
21 Could The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Ownership Structure Tell Us Something Useful?
22 Is Fulcrum Therapeutics Inc (FULC) Stock About to Get Hot Thursday?
23 Fulcrum Therapeutics Completes $68.5 Million Private Placement
24 Duchenne Muscular Dystrophy Drugs Market Opportunities And Key Insights 2021 – Clark County Blog
25 Fulcrum Therapeutics Announces Initiation of Multi-Center Phase 3 (LOSVID) Trial with Losmapimod for Hospitalized COVID-19 PatientsFulcrum receives early notification from US Food and Drug Administration (FDA) that study may proceed
26 Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast
27 Why Earnings Season Could Be Great for Fulcrum Therapeutics (FULC)
28 MyoKardia And Fulcrum Therapeutics Collaborate
29 Fulcrum Therapeutics Appoints Pamela Strode, Seasoned Industry Executive, to Lead Regulatory Affairs Team
30 Acceleron and Fulcrum Therapeutics Announce Pulmonary Research and Discovery Collaboration Agreement
31 H.C. Wainwright Reaffirms Their Buy Rating on Fulcrum Therapeutics (FULC)
32 Fulcrum Therapeutics to Host Second Quarter 2020 Financial
33 Fulcrum Therapeutics
34 Fulcrum Therapeutics Acquires Global Rights to Losmapimod, a Potential Disease-Modifying Therapy for Facioscapulohumeral Muscular Dystrophy
35 Fulcrum Therapeutics Announces $80 Million Series B Financing
36 Fulcrum stumbles in PhII of old GSK drug, sending shares tumbling
37 What is the Market's View on Fulcrum Therapeutics Inc (FULC) Stock's Price and Volume Trends
38 Fulcrum Therapeutics Announces Complete Data from Phase 1 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy
39 $FULC Fulcrum Therapeutics Reports Q3 Loss Per Share $0.70
40 Sickle cell disease: scientists are developing a game-changing treatment
41 Fulcrum Therapeutics Announces Initiation of ReDUX4, a Phase 2b Clinical Trial of Losmapimod for FSHD
42 Fulcrum Therapeutics Licenses Failed GSK Drug for Possible Muscular Dystrophy Indication
43 FDA Puts Investigational FSHD Therapy Losmapimod on Fast Track
44 Fulcrum Therapeutics Announces Pricing of Initial Public Offering
45 Fulcrum Therapeutics Appoints Biotech Executive Bryan Stuart as Chief Operating Officer
46 Fulcrum's FTX-6058 Shows Promise as SCD Therapy in Disease Models
47 Movers & Shakers, Dec. 18 | BioSpace
48 Fulcrum Therapeutics (FULC) Up 65% In A Month, IPO Lockup Expires On Jan.14
49 Fulcrum Therapeutics IPO: What You Need To Know
50 FTSE 100 down as Fed points to hikes in 2023; Whitbread pleases | Finance News |
51 Phase 1 Trial of Oral FTX-6058 to Promote Fetal Hemoglobin Set to Open
52 Phase 2b Trial of Fulcrum's Oral FSHD Treatment, Losmapimod, Fully...
53 Eliem Therapeutics Emerges from Stealth with $80 Million Invested to Progress Multiple Clinical Stage Assets Targeting Neuronal Excitability Disorders
54 Other news to note for April 12, 2021 | 2021-04-12
55 TScan Therapeutics Appoints Katina Dorton, J.D., M.B.A., to Its Board of Directors
56 Monte Rosa Therapeutics Expands Senior Management Team
57 Health tech funding snapshot—Data analytics startup Axtria banks $150M; Binx Health nabs $104M for at-home testing
58 The Development and Treatment Potential of FTX-6058
59 Pandion Therapeutics Appoints Katina Dorton to its Board of Directors
60 Third Rock Ventures launches Fulcrum Therapeutics; Michael Green of UMMS a co-founder
61 Top 10 Most-read Muscular Dystrophy Stories of 2020
62 Acceleron and Fulcrum Strike Deal to Address Pulmonary Diseases
63 CORRECTING and REPLACING Fortis Therapeutics Closes $40 Million Series A Financing to Advance Novel Anti-CD46 Therapeutic to Treat Late-Stage Prostate Cancer and Multiple Myeloma
64 Diem Nguyen tapped to lead 'point of inflection' at Xalud Therapeutics; Diana Escolar dances her way to Avrobio CMO
65 Virtual meeting delivers first time drug structures
66 Fulcrum Therapeutics Launched with Robert Gould at Helm
67 Scanning the horizon for future Covid-19 treatments
68 FDA Grants Orphan Drug Status to Losmapimod, Potential FSHD Therapy
69 FULC Price Target, Analyst Ratings and Predictions (Fulcrum Therapeutics)
70 Flare Therapeutics Raises $82M in Series A Financing
71 Clinical Catch-Up: October 5-9
72 Sickle cell disease: Investigating a new drug
73 Bulfinch Enlists Colliers to Lease Lab and Office Building in Cambridge
74 Amit Hasija as Joins Fulcrum Therapeutics as Chief Business Officer
75 68 Biggest Movers From Yesterday
76 Eliem Therapeutics Launches with $80M in Financing
77 Fulcrum Launches Phase 2b Trial of Losmapimod for FSHD
78 Horizon and fledgling Fulcrum team up on using CRISPR for genetic diseases
79 The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies
80 Friedreich Ataxia Pipeline Review, H2 2020
81 Annual Changes to the Nasdaq Biotechnology Index NEW YORK, Dec. 11, 2020
82 How anti-ageing drugs could boost COVID vaccines in older people
83 Fulcrum repurposes failed GSK drug for rare disease
84 Merck keeps it in the family as Robert Davis hands the CFO keys to Caroline Litchfield; Gilead loses Diana Brainard, with virology exec becoming CEO of AlloVir
85 Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & More
86 MyoKardia Reports Third Quarter 2020 Financial Results
87 Clinical Catch-Up: June 22-26
88 MyoKardia Reports Second Quarter 2020 Financial Results
89 First-quarter catalysts for the smaller players
90 Duchenne Muscular Dystrophy Pipeline Review, H2 2020: Therapeutics Assessment, Competitive Landscape, Drug Profiles, Dormant Projects
91 Stocks To Watch: Eyes On Best Buy, Vaccines And Holiday Cheer
92 BARDA no longer funding immunomodulators as support for the therapeutic class to treat COVID-19 grows
93 The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
94 Financings for Jan. 20, 2021 | 2021-01-20
95 The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company
96 The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions
97 Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
98 NodThera Appoints Chief Medical Officer and Chief Financial Officer
99 PTC Therapeutics – PTC299
100 Fulcrum seeks FSHD therapy in deal for dropped GSK asset